Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Landskrona – page 11

1 405 clinical trials in Landskrona, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Landskrona at a glance
1 405
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 405 trials in Landskrona

Open in trial search

Sepsis+1

Recruiting

Acetylcysteine for Adults with Acute Infection or Sepsis and Liver Dysfunction

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Region Hovedstaden

Indocyanine Green Fluorescence Imaging for Flap Perfusion in Head and Neck Cancer Reconstruction Surgery

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Indocyanine Green
  • Sponsor:Region Skane

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Neoplasm

Recruiting

Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Telisotuzumab adizutecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

AUR200 for Patients with Generalized Myasthenia Gravis

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AUR200
  • Sponsor:Aurinia Pharmaceuticals Inc.

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Study to evaluate if colchicine reduces inflammation in patients with chronic coronary artery disease

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Region Hovedstaden

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Arsenic Trioxide
  • Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

Stomatitis+1

Recruiting

A study to compare the effectiveness of bupivacaine hydrochloride monohydrate and lidocaine hydrochloride for treating mouth sores in patients with head and neck cancer.

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bupivacaine hydrochloride monohydrate
  • Sponsor:OncoZenge AB

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Landskrona

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical research focusing on heart failure with preserved ejection fraction (HFpEF), evaluating the effectiveness of spironolactone and eplerenone treatments combined with standard care approaches.

  • Heart Failure Management
  • Cardiovascular Outcomes
  • Treatment Optimization

The research aims to reduce hospitalization rates and improve cardiovascular survival outcomes through registry-based methodologies.

02 Urological Oncology

Groundbreaking research in non-muscle invasive bladder cancer treatment, comparing the efficacy of adjuvant therapies using gemcitabine versus mitomycin in intermediate-risk cases.

  • Bladder Cancer Treatment
  • Recurrence Prevention
  • Post-surgical Care

This study focuses on improving recurrence-free survival rates following transurethral tumor resection procedures.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.